Figure and Table Legends:
Table 1. Baseline demographic characteristics of the
participants who received the booster dose
Figure 1: The design of the study.
Figure2: Neutralizing antibody levels after BNT162b2 and
CoronaVac booster doses. A- PRNT50 titers at baseline, one
month and three months after boosters. Black lines are GMT=geometric
mean titer (*P<0.001; **P<0.05). B- Changes
in neutralizing antibody levels for each individual during a 3-month
period. Dots represent neutralizing antibody titers for individuals in
the population.
Figure 3. The proportion of specific T cell subpopulations
after activation with SARS-CoV-2 S peptide pool. A-CD4+ cell ratio at baseline, one month and three
months after boosters. B- CD8+ at baseline,
one month and three months after boosters. Dots represent T cell ratios
for individuals in the population. Black lines are median values of each
population.
Figure 4. The ELISPOT results of T cells after incubation with
SARS-CoV-2 S peptide pool. A - IFN-γ response at baseline, one
month and three months after boosters. B- IL-2 response at
baseline, one month and three months after boosters. Dots represent T
cell ratios for individuals in the population, (*P<0.001;
**P<0.05).
Figure 5. The ratio of
CD8+CD38+CD69+ and
CD4+CD38+CD69+cells after BNT162b2 and CoronaVac boosters. A-CD8+CD38+CD69+cell ratio at baseline, one month and three months after boosters.B- CD4+CD38+CD69+cell ratio at baseline, one month and three months after boosters. Dots
represent T cell ratios for individuals in the population.
(*P<0.05)